Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism

Molecular Genetics and Metabolism

Volumn 109, Issue 4, 2013, Pages 319-328

  Camp, Kathryn M ^a   Lloyd Puryear, Michele A ^a   Yao, Lynne ^b   Groft, Stephen C ^c   Parisi, Melissa A ^d   Mulberg, Andrew ^b   Gopal Srivastava, Rashmi ^c   Cederbaum, Stephen ^e   Enns, Gregory M ^f   Ershow, Abby G ^g   Frazier, Dianne M ^h   Gohagan, John ^a   Harding, Cary ⁱ   Howell, R Rodney ^j   Regan, Karen ^a   Stacpoole, Peter W ^k   Venditti, Charles ^l   Vockley, Jerry ^m   Watson, Michael ⁿ   Coates, Paul M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j UNIVERSITY OF MIAMI   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁿ American College of Medical Genetics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BIOLOGICAL PRODUCT; CARBOHYDRATE; CARGLUMIC ACID; ENZYME; FAT; MINERAL; PHENYLALANINE 4 MONOOXYGENASE; PHENYLALANINE AMMONIA LYASE; PROTEIN; SAPROPTERIN; VITAMIN;

ARTIFICIAL MILK; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; CONFERENCE PAPER; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG DESIGN; DRUG INDUSTRY; DRUG SAFETY; ENZYME DEFECT; EVIDENCE BASED MEDICINE; FAMILY; FOOD AND DRUG ADMINISTRATION; FOOD INDUSTRY; FOOD SAFETY; GENETIC SERVICE; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PRACTITIONER; HEALTH PROGRAM; HUMAN; INBORN ERROR OF METABOLISM; KNOWLEDGE; METABOLISM; NAGS DEFICIENCY; NATIONAL HEALTH ORGANIZATION; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SCREENING; NUTRITIONAL SUPPORT; ORPHAN DRUG ACT; PATIENT ADVOCACY; PATIENT SAFETY; PHENYLKETONURIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PSYCHOSOCIAL CARE; PUBLIC HEALTH; RARE DISEASE; REIMBURSEMENT; THERAPY EFFECT; UNITED STATES; DIET; DIET THERAPY; DISEASE MANAGEMENT; DRUG ADMINISTRATION ROUTE; GENETICS; NUTRITION;

DIET; DIETARY SUPPLEMENTS; DISEASE MANAGEMENT; DRUG ADMINISTRATION ROUTES; HUMANS; METABOLISM, INBORN ERRORS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; RARE DISEASES; UNITED STATES;

EID: 84880811177     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.05.008     Document Type: Conference Paper

References (60)

1. Camp K., Lloyd-Puryear M.A., Huntington K. Nutritional treatment for inborn errors of metabolism: Indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol. Genet. Metab. 2012, 107:3-9.
2. Cunningham G.C. Two years of PKU testing in California: the role of the laboratory. Calif. Med. 1969, 110:11-16.
3. U.S.Congress, Office of Technology Assessment Healthy Children: Investing in the Future 1988, OTA-H-345, U.S. Government Printing Office, Washington, DC.
4. Watson M.S., Mann M.Y., Lloyd-Puryear M., Rinaldo P., Howell R.R. American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics 2006, 117:5296-5307.
5. Baby's First Test Available At:, (Accessed March 26, 2013). http://www.babysfirsttest.org/.
6. Gentile J.K., Ten Hoedt A.E., Bosch A.M. Psychosocial aspects of PKU: hidden disabilities-a review. Mol. Genet. Metab. 2010, 99(Suppl. 1):S64-S67.
7. Burton B.K., et al. A diversified approach for PKU treatment: routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. Mol. Genet. Metab. 2013, 108:8-12.
8. Public Law 97-414 Available At:, (Accessed March 26, 2013). http://history.nih.gov/research/downloads/PL97-414.pdf.
9. U.S.Food and Drug Administration Orphan Drug Act Available At:, (Accessed March 26, 2013). http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/OrphanDrugAct/default.htm.
10. National Institutes of Health Office of Rare Diseases Research Rare diseases information Available At:, (Accessed March 26, 2013). http://rarediseases.info.nih.gov/Resources/Rare_Diseases_Information.aspx.
11. National Institutes of Health Office of Rare Diseases Research Rare Diseases Information Center (GARD) Available At:, (Accessed March 26, 2013). http://rarediseases.info.nih.gov/GARD/Default.aspx?PageID=4.
12. U.S.Food and Drug Administration Guidance for industry: frequently asked questions about medical foods Available At:, (Accessed March 26, 2013). http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/MedicalFoods/ucm054048.htm.
13. National Institutes of Health, National Center for Advancing Translational Sciences Available At:, (Accessed March 14, 2013). http://www.ncats.nih.gov/research/cts/ctsa/ctsa.html.
14. U.S.Government Printing Office Public Law 107-280-Rare Diseases Act of 2002 Available At:, (Accessed March 26, 2013). http://www.gpo.gov/fdsys/pkg/PLAW-107publ280/content-detail.html.
15. Rare diseases clinical research network (RDCRN) Available At:, (Accessed March 26, 2013). http://rarediseases.info.nih.gov/ASP/resources/extr_res.asp.
16. Newborn screening translational research network (NBSTRN) (Accessed March 26, 2013). https://www.nbstrn.org/.
17. U.S.Food and Drug Administration (Accessed March 26, 2013). http://www.fda.gov/aboutfda/whatwedo/default.htm.
18. Govtrack.us. S. 3187 (112th): Food and Drug Administration Safety and Innovation Act Available At:, (Accessed March 26, 2013). http://www.govtrack.us/congress/bills/112/s3187/text.
19. U.S.Food and Drug Administration Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products Available at:, (Accessed March 26, 2013). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078749.pdf.
20. U.S.Food and Drug Administration Dietary supplements Available At:, (Accessed March 26, 2013). http://www.fda.gov/food/dietarysupplements/default.htm.
21. U.S.Food and Drug Administration Federal Food, Drug, and Cosmetic Act (FD&C Act) Available At:, (Accessed March 26, 2013). http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/default.htm.
22. National Institutes of Health.Office of Dietary Supplements Dietary supplements: what you need to know Available At:, (Accessed March 26, 2013). http://ods.od.nih.gov/HealthInformation/DS_WhatYouNeedToKnow.aspx.
23. U.S.Food and Drug Administration Inspections, compliance, enforcement, and criminal investigations Available At:, (Accessed March 26, 2013). http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074948.htm.
24. Scannell J.W., Blanckley A., Boldon H., Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 2012, 11:191-200.
25. Paul S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
26. (Accessed March 26, 2013). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.ReportsMenu.
27. Pariser A.R., Slack D.J., Bauer L.J., Warner C.A., Tracy L.A. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010. Drug Discov. Today 2012, 17:898-904.
28. National Institutes of Health Research Portfolio Online Reporting Tools (RePORT). Research project grants: success rates by type, activity, and institute/center (fiscal years 2002-2011) Available At:, (Accessed March 26, 2013). http://report.nih.gov/success_rates/index.aspx.
29. Sasinowski F.J. Quantum of effectiveness evidence in FDA's approval of orphan drugs cataloguing FDA's flexibility in regulating therapies for persons with rare disorders. Drug Inf. J. 2012, 46:238-263.
30. BioMarin® BioMarin announces decision to start phase 3 program for PEG-PAL in 2Q Available At:, (Accessed March 26, 2013). http://investors.bmrn.com/releasedetail.cfm?ReleaseID=716661.
31. Singh R.H., Kaczmarczyk M.M. Standards of professional practice for genetic metabolic dietitians. Genet. Med. 2008, 10:290-293.
32. Camp K., Rohr F.J. Advanced practitioners and what they do that is different, roles in genetics. Top. Clin. Nutr. 2009, 23:219-230.
33. Takach M. About half of the states are implementing patient-centered medical homes for their Medicaid populations. Heal. Aff. 2012, 31:2432-2440.
34. Henderson S., Princell C.O., Martin S.D. The patient-centered medical home. AJN 2012, 112:54-59.
35. European Commission International Rare Diseases Research Consortium Available At:, (Accessed May 8, 2013). http://ec.europa.eu/research/health/medical-research/rare-diseases/irdirc_en.html.
36. Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development 2011, National Academies Press, Washington, DC.
37. Fiorentino R., Liu G., Pariser A.R., Mulberg A.E. Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases. J. Allergy Clin. Immunol. 2012, 130:613-616.
38. National Coordinating Center for the Regional Genetic and Newborn Screening Service Collaboratives, Available At:, (Accessed March 26, 2013). http://www.nccrcg.org/AM/Template.cfm?Section=Home5.
39. Griggs R.C., et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol. Genet. Metab. 2009, 96:20-26.
40. US Food and Drug Administration Code of Federal Regulations Title 21: Approval of an application and an abbreviated application 2012, Pt. 314.105, US Government Printing Office, Washington, DC, USA.
41. Murray D.M., Pennell M., Rhoda D., Hade E.M., Paskett E.D. Designing studies that would address the multilayered nature of health care. J. Natl. Cancer Inst. Monogr. 2010, 40:90-96.
42. U.S.Food and Drug Administration CFR-Code of Federal Regulations, Title 21. 21 CFR 314 & 601 Available At:, (Accessed March 26, 2013). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=314.
43. U.S.Food and Drug Administration Available At:, (Accessed March 26, 2013). http://www.fda.gov.
44. Ravina B., et al. Local Institutional Review Board review of a multicenter trial: local costs without local context. Ann. Neurol. 2010, 67:258-260.
45. Infectious Disease Society of America Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts. Clin. Infect. Dis. 2009, 258-260.
46. Greene S., Geiger A.M. A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval. J. Clin. Epidemiol. 2006, 59:784-790.
47. Pogorselska M., et al. Changes in the Institutional Review Board submission process for multicenter research over 6years. Nurs. Outlook 2010, 58:181-187.
48. Marsolo K. Approaches to facilitate Institutional Review Board approval of multicenter research studies. Med. Care 2012, 50:S77-S81.
49. Hirschfield S., Slutsman J. Overview of the federation model for IRB review of the National Children's Vanguard Study 2011, Secretary's Advisory Committee on Human Research Protections.
50. Cooksey J.A., et al. The state of the medical geneticist workforce: findings of the 2003 survey of American Board of Medical Genetics certified geneticists. GIM 2006, 7:439-443.
51. Brotherton S.E., Etzel S.I. Graduate medical education, 2008-2009. JAMA 2009, 302(12):1357-1372.
52. Royal College of Physicians Consultant Physicians Working with Patients-the Duties, Responsibilities and Practice for Physicians, 3rd ed. Royal College of Physicians, London, 2004
53. Michael Watson, ACMD personal, communication, March 14 2013.
54. American Dietetic Association Compensation and benefits survey of the dietetics profession Available At:, (Accessed May 8, 2013). https://www.eatright.org/Shop/Product.aspx?id=6442469548.
55. American Academy of Pediatrics National Center for Medical Home Implementation. Genetics in primary care institute Available At:, (Accessed March 26, 2013). http://www.medicalhomeinfo.org/gpci.aspx.
56. U.S.Food and Drug Administration Advancing regulatory science Available At:, (Accessed March 26, 2013). http://www.fda.gov/scienceresearch/specialtopics/regulatoryscience/default.htm.
57. Sebelius K. Building a stronger foundation for a new century of treatments and cures. Heal. Aff. 2011, 30:81-83.
58. National Institutes of Health Grants and funding Available At:, (Accessed March 26, 2013). http://grants.nih.gov/grants/funding/submissionschedule.htm.
59. Newborn screening in the genomic era: setting a research agenda Available At:, (Accessed March 26, 2013). https://www.genome.gov/Pages/PolicyEthics/StaffArticles/Newborn_Screening_Meeting_Summary.pdf.
60. Scharfe C., et al. Mapping gene associations in human mitochondria using clinical disease phenotypes. PLoS Comput. Biol. 2009, 5:e1000374.